1. Introduction {#sec1}
===============

*α*B-crystallin/HspB5 (*α*-BC) is one member of the mammalian small heat shock protein family which consists of ten known members from HspB1 to B10. Though isolated from the crystallin lens, it has been described in a broad number of tissues and organs including the brain, skeletal muscle, heart, and kidney, and it is shown to implicate in many diseases, such as multiple sclerosis (MS), Guillain-Barre syndrome (GBS), Alexander disease, epilepsy, Down syndrome, familial amyotrophic lateral sclerosis (FALS), familial amyloidotic polyneuropathy and chronic inflammatory demyelinating polyneuropathy \[[@B13]--[@B33]\].

It has been reported that *α*-BC functions as molecular chaperones by binding with denatured protein under stress in a reversible equilibrium state. In addition, the specific interaction between *α*-BC and cytoskeletal structures in cardiac and skeletal myocytes has been proved, and the interaction is enhanced after stress, which contributes to increased stress tolerance \[[@B8]--[@B41]\]. The increased expression of *α*-BC in cerebral arteriovenous malformations (AVMs) is also associated with maintenance of the intermediate fibre (IF) network, which increases wall tension caused by dilating vessels and the hemodynamic stress surrounding \[[@B12]\], another research found out that *α*-BC significantly suppressed the ADP-induced secretions of both platelet-derived growth factor (PDGF) and serotonin by inhibition of HSP27 phosphorylation via p44/p42 MAPK and p38 MAPK \[[@B11]\]. According to its antihemodynamic stress and antiplatelet aggregation effects, we speculate that it plays an important role in ischemic vascular diseases. In addition, research data identified *α*-BC as downstream effector of calcineurin-induced protection against apoptosis, \[[@B4]\] and it is sufficient to inhibit apoptosis by interacting with apoptosis-associated factors such as Bax, Bcl-XS, p53, caspase-3 and its activators \[[@B37]--[@B17]\].

Moreover, *α*-BC is shown to exhibit a potential role in neurological diseases involving protection of atrophy in myopathy, prevention of abnormal protein aggregation in neurodegenerative diseases, and involvement in immune responses of nervous system \[[@B30]\]. However, it is a relative newcomer in brain ischemia diseases.

Cytoskeleton is composed of microtubule, microfilament, and intermediate filament, and it is involved in maintaining cell structure and participating in cellular kinesis, cleavage, and nutrient substance transportation, and it also plays a crucial role in signal transduction. Both heat stress and ischemia can cause extensive damage to the cytoskeleton, and early change in cytoskeleton is a sensitive index of affected cells \[[@B2]\]. Microtubule-associated protein-2 (MAP-2) is a neuron-restricted cytoskeleton protein \[[@B44]\] and serves as a substrate for most of protein kinases and phosphatases present in neurons. Moreover, MAP-2 may perform many functions including the nucleation and stabilization of microtubules and the regulation of organelle transport within axons and dendrites in response to different extracellular signals \[[@B44], [@B34]\]. Fujita et al. reveal that *α*-BC binds microtubules (MTs) via microtubule-associated proteins (MAPs) and gives the MTs resistance to calcium-induced disassembly \[[@B46]\].

In this study, we showed that *α*-BC was coexpressed with MAP-2 in cortex neurons and also in a group of MAP-2-negative glia cells in subcortex Gerbil brains by double immunofluorescence. Staining characteristic of *α*-BC in these cells is the concentrated cytoplasm staining around the nucleus and extending to dendrites. While subjected to 10-minute bilateral carotid artery occlusion (BCAO), the expression of *α*-BC was gradually upregulated from 6 hours to 7 days after reperfusion. However, MAP-2-positive neurons showed significant decrease in number and staining intensity as early as 6 hours after reperfusion and then recovered gradually, which is accompanied by the increase of *α*-BC. We speculate that *α*-BC plays an important role in brain ischemia.

2. Materials and Methods {#sec2}
========================

2.1. Animals and Surgery {#sec2.1}
------------------------

All animal experiments were conducted in accordance with National Institutes of Health and institutional guidelines. Male Mongolian Gerbils (Hangzhou, Zhejiang, China) weighing 80--90 g were housed in standard temperature (22 ± 1°C) and light-controlled (light on 07:00--20:00) environment with ad libitum access to food and water. The animals were randomly divided into two groups. They were sham and BCAO groups, and each group was divided into four time points (6 hours, 24 hours, 72 hours, and 7 days after surgery). In addition, there was a group of Gerbils without any treatment. There were eight animals in each group. Before surgery, each animal was anesthetized by peritoneal injection with 3% pentobarbital (30 mg/kg). Bilateral carotid artery occlusion (BCAO) was carried out as described by Hu et al. \[[@B47]\] Occlusion was maintained for 10 minutes, and this was followed by reperfusion for 6 h, 24 h, 72 h, and 7 days. In sham-operated animals, the arteries were exposed but not occluded. The wound was then well sutured, and the animals were allowed to recover. The body temperature was maintained at 36-37°C during the surgery with a heating pad. The success of this ischemia/reperfusion model was further proved and evaluated by HE staining of Gerbil cerebral cortex with the following indications: intracellular or interstitial edema, inflammatory infiltration, and gliosis.

2.2. Immunohistochemical Methods {#sec2.2}
--------------------------------

At the time points, the animals were perfused transcardially with 30 mL of 0.9% saline followed by 100 mL of 4% paraformaldehyde solution. The brains were removed and placed in 10% formalin for less than 24 h, processed, and embedded in paraffin wax. Coronal sections (5 *μ*m) of brain were taken using a microtome. Immunohistochemical staining was performed on paraffin-embedded coronal sections (5 *μ*m). Sections were deparaffinized and rehydrated. Sections were then incubated in 0.3% hydrogen peroxide (H~2~O~2~) for 5 min to block endogenous peroxidase activity, rinsed, incubated in pepsin/HCl for 30 min, rinsed in water, and then rinsed in PBS (PH 7.2--7.6, 0.02 M). Normal goat serum (1.5% in PBS) was used as a preblock for 20 minutes after which the sections were incubated with primary antibody *α*-BC (Santa Cruz, FL 175, USA) 1 : 150 and primary antibody MAP-2 (Boster, BA0056), respectively, at 37°C in a humidified immunostaining chamber for 1 hour. Sections were then rinsed in PBS (4 × 10 min) and incubated in biotinylated secondary antibody for 20 min at room temperature, after which they were again washed in PBS (3 × 10 min). Subsequently, sections were incubated in avidin-conjugated horseradish peroxidase for 20 min at room temperature and washed in PBS (4 × 5 min). Finally, sections were visualized by using 0.05% diaminobenzidine and 0.02% H~2~O~2~ until color developed and then washed in tap water, dehydrated, coverslipped using DPX mountant, and examined under a light microscope. Expression index: under high magnification (10 × 40) or oil microscope (10 × 100), count the numbers of positive cells with cytoplasm brown particles per 1000 cells in randomly selected areas of each slice.

2.3. Double Immunofluorescence {#sec2.3}
------------------------------

Immunofluorescence double labeling was also performed on paraffin-embedded coronal sections (5 *μ*m). Sections were deparaffinized and rehydrated in a normal way. Primary antibodies were diluted at 1 : 100 for anti-*α*-BC (Santa Cruz, FL-175, USA) and at 1 : 150 for anti-MAP-2 (Boster, BA0056) antibodies. For double immunostaining, 1 : 200 TRITC-labeled anti-rabbit IgG (Boster) was used as the secondary antibody for anti-*α*-BC antibodies. After washing with 0.1 M PH7.4 PBS, sections were incubated with 1 : 200 FITC-conjugated anti-mouse IgG (Boster) for anti-MAP-2-antibodies in PBS for 30 min at room temperature. Sections were observed by fluorescence microscope under 546 nm and 490 nm wavelength excitation light, TRITC-labeled a-BC-positive cells presented red fluorescence, and FITC-labeled MAP-2-positive cells presented green fluorescence.

3. Results {#sec3}
==========

3.1. Expression of *α*B-Crystallin in Cortex Neurons and a Group of Glia Cells after Ischemia/Reperfusion (I/R) Injury {#sec3.1}
----------------------------------------------------------------------------------------------------------------------

In the brain slices of Gerbil BCAO/reperfusion model, immuno-fluorescence staining of cerebral cortex showed MAP-2-labeled neurons with green fluorescence and *α*-BC-positive cells with red fluorescence ([Figure 1](#fig1){ref-type="fig"}); we found that the fluorescence of *α*-BC largely overlapped with that of MAP-2 in cortical neurons ([Figure 1](#fig1){ref-type="fig"}: III and III′), suggesting the coexpression and colocation of both proteins in neurons after ischemia/reperfusion (I/R) injury. Thus, *α*-BC may interact with MAP-2 to further protect the microtubules (MTs) in cortical neurons after I/R injury, while in subcortical brain tissue slices, we also found out a group of MAP-2-negative nonneuronal glia cells which were *α*-BC positive ([Figure 1](#fig1){ref-type="fig"}: I, I′ and II, II′) (white arrow head), suggesting that *α*-BC was also expressed in a group of glia cells.

3.2. Annular Cytoplasmic Expression of *α*B-Crystallin in Glia Cells {#sec3.2}
--------------------------------------------------------------------

The nuclei of *α*-BC-positive glia cells were surrounded by densely stained annular cytoplasm, and the staining is further extended into proximal segments of cytodendrites ([Figure 1](#fig1){ref-type="fig"}: IV, V and VI, VII). Expression of *α*-BC-in neurons was relatively stable during I/R injury. While, a significant increment in the staining concentration and the number of typical *α*-BC positive glia cells was detected after BCAO/reperfusion (Figures [2(a)](#fig2){ref-type="fig"}--[2(d)](#fig2){ref-type="fig"}), the upregulated expression appeared after 6-hour reperfusion and sustained for 7 days. The expression of MAP-2 was prominently in neurons and less detected in glia cells, which was further confirmed by double immunofluorescent staining ([Figure 1](#fig1){ref-type="fig"}: I, I′ and II, II′).

3.3. The Expression of MAP-2 and *α*-BC in the Normal and Ischemia/Reperfusion Gerbil Brains {#sec3.3}
--------------------------------------------------------------------------------------------

Previous researches suggest that *α*-BC may interact with cytoskeleton components to give the first line of defense during ischemia/reperfusion injury \[[@B26]\]. We use DAB staining to observe the expression of *α*-BC and MAP-2 in Gerbil brain slices. Expression index is calculated by counting the numbers of positive cells with cytoplasm brown particles per 1000 cells in randomly selected areas of each slice under high magnification (10 × 40). Results indicated that *α*-BC was induced in the early BCAO/reperfusion brain as soon as 6 hours after reperfusion, while MAP-2 was significantly reduced immediately after BCAO/reperfusion to almost 20% of normal level followed by a slow recovery (Figures [2(a)](#fig2){ref-type="fig"}--[2(h)](#fig2){ref-type="fig"}; [Figure 3](#fig3){ref-type="fig"}). The expression index trendgram ([Figure 3](#fig3){ref-type="fig"}) of *α*-BC and MAP-2 shows that the recovered expression of MAP-2 following sharp decrease after I/R injury is accompanied with the upregulation of *α*-BC. The correlation between MAP-2 and *α*-BC during brain I/R ischemia suggests that the molecular chaperone *α*-BC may protect neurons by preventing the degradation of denatured MAP-2.

4. Discussion {#sec4}
=============

*α*-BC is constitutively expressed in the central nervous system (CNS), and its level of expression in the normal central nervous system is low and appears to be centralized to glia cells, both astrocytes and oligodendrocytes \[[@B39]\]. Many neurodegenerative disorders including Alzheimer\'s Disease, and Parkinson\'s disease, amyotrophic lateral sclerosis (ALS) are characterized by conformational changes in proteins that result in misfolding, aggregation, and intra- or extraneuronal accumulation of amyloid fibrils. *α*-BC, as a molecular chaperone, provides a first line of defense against misfolded, aggregation-prone proteins in central nervous system (CNS) \[[@B32]\], while, Narayanan et al. \[[@B28]\] demonstrated that in the presence of *α*-BC, A*β* became efficiently oxidized with increased neurotoxicity and the inability to form fibrillar structures. Results are paradoxical, and the exactly role of *α*-BC still remains a matter to be concerned about.

Multiple sclerosis (MS) is a chronic neurodegenerative disease of the CNS with extensive demyelination, loss of oligodendrocytes, and axonal degeneration. In MS, T-cell response to *α*-BC is much stronger than all other components of myelin in MS and is considered to be a potential autoantigen \[[@B49]\]. Ousman et al. suggested that the immune response against *α*-BC in multiple sclerosis would exacerbate inflammation and demyelination, which can be countered by recombinant CRYAB for therapy of ongoing disease \[[@B30]\]. However, research by Rothbard et al. demonstrated that the putative anti-HspB5/*α*-BC Abs from 23 MS patients cross-react with 7 other members of the human small Hsp family and were equally present in normal plasma. These results refute much of the serological data used to assign *α*-BC as an autoantigen \[[@B33]\].

Alexander disease (AxD) is a primary disorder of astrocytes caused by dominant mutations in the gene for glia fibrillary acidic protein (GFAP). In AxD mouse models, loss of CRYAB results in increased mortality, whereas elevation of CRYAB rescues animals from terminal seizures by regulation of GFAP assembly and reduction in CNS stress response \[[@B13]\].

In our BCAO/reperfusion Gerbil model, the *α*-BC immune-reactivity is detected in the cytoplasm of both neurons and a group of glia cells, which is in agreement with previous research by Piao et al. \[[@B5]\]. In their research of rat brain after middle cerebral artery occlusion (MCAO), they demonstrated one group of glia cells which only expressed *α*-BC and were p38*β*MAPK or MAPKAPK-2 negative; a further study revealed that those cells were oligodendrocytes. Moreover, in subcortical Gerbil brains, *α*-BC immune reactivity was upregulated gradually from 6 hours after reperfusion to peak at around 7 days after. An increment was observed in the number and the staining concentration of *α*-BC-positive cells. Staining feature of these glia cells is described as annular cytoplasmic dense staining, which is distributed around the nucleus and extended into proximal segments of cytodendrites.

Recently, several studies have investigated the close interaction between *α*B-crystallin and cytoskeletal components in nonneural cells, such as cardiac muscle cells, skeletal muscle cells, vascular endothelial cells, collagenoblasts, and osteoblasts (reviewed by Hu and Li \[[@B48]\]). In unstimulated cardiac myocytes, biochemical studies indicate that *α*-BC associates with cytoskeletal components and is highly soluble and remains in the cytosolic fraction; heat or ischemia triggers rapid translocation of *α*-BC into the insoluble cytoskeletal/nuclear fractions \[[@B3]\] with enhanced interaction with cytoskeletal components \[[@B8]--[@B41]\]. Thus, it is important for *α*-BC to confer early protection of ischemic cardiac. In addition, recent researches indicate that *α*-BC can suppress the aggregation of platelets \[[@B11]\] and provide protection under hemodynamic stress \[[@B12]\] which prompts its potential significance in vascular diseases.

MAP-2 is a cytoskeleton component protein found mainly in dendrites and soma of neuronal cells in most regions of central nervous system, and it has been used extensively as a very sensitive and specific marker for neuronal differentiation during the last two decades \[[@B23]\]. It can modulate the assembling of tubulin/microtubule which commonly allows the cell to respond mechanically to the environment. Loss of MAP-2 by degradation of calpain I in both the striatum and hippocampus after ischemia in the Gerbil forebrain was found to occur earlier than spectrin degradation by Western blot analysis \[[@B25]\]. Those results suggest that dendritic loss of MAP-2 immunoreactivity after ischemia might participate in the initial phase of neuronal cytoskeleton dysfunction and might become a first sign of neurodegeneration. Researches of permanent middle cerebral artery occlusion (MCAO) by Dawson and Hallenbeck \[[@B6]\] also elicited a rapid reduction in MAP-2 immunostaining that was visible 1 h after MCAO, indicating that MAP-2 could be used in acute brain injury following focal ischemia as a sensitive and quantifiable indicator. Here, we used MAP-2 as a neuron marker and found that *α*-BC and MAP-2 were colocated in neurons of cerebral cortex in Gerbil BCAO/reperfusion model by double immunofluorescence staining; in addition, a group of MAP-2-negative glia cells also strongly expressed *α*-BC in subcortical brain, suggesting the broad expression of *α*-BC in the CNS. When confronted with ischemia/reperfusion injury, the MAP-2-positive neurons were significantly reduced immediately after reperfusion to almost 20% of normal level followed by a slow recovery, which was consistent with previous researches. The recovered expression of MAP-2 following sharp decrease was accompanied with sustained upregulation of *α*-BC since the third day after reperfusion. The correlation between MAP-2 and *α*-BC in cortex neurons during brain I/R ischemia suggests that the molecular chaperone *α*-BC may protect neurons by preventing the degradation of MAP-2 via enhanced interaction.

All complex nervous systems consist of two main cell types, neurons and glia cells. The evolution of increasing complexity in the nervous system is accompanied by a steady rise in glia cell number. Oligodendrocytes in the central nervous system (CNS) produce the myelin sheath of neurons by wrapping of its plasma membrane extensions around the axon, and compacting with the stacked membrane bilayers. They also modify the axonal cytoskeleton and the rate of vesicular transport along the axons \[[@B7]--[@B10]\]. The reciprocal communication between neurons and oligodendrocytes is important for the development of the nervous system. Furthermore, there is mounting evidence that neuron-glia communication has a role in the pathogenesis of many neurological diseases.

During brain ischemia, neurons and glia cells upregulated the expression of *α*-BC against the injuries caused by free radicals, calcium overload, releasing of proteinase, and so on probably through at the least four aspects below (reviewed by Hu and Li \[[@B48]\]): (1) translocating to myofilament and nuclear structures where the chaperone functions confer cytoskeleton stabilization; (2) associating with apoptosis regulators such as Bax, Bcl-XS, p53, caspase-3, and its activators conferring apoptosis; (3) interacting with other cellular proteins, especially those denatured proteins and keeping them in a soluble state waiting for refolding; (4) translocating to mitochondria, where it is phosphorylated and contributes to modulating mitochondrial damage \[[@B43]\]. In addition, elevated *α*-BC expression of glia cells may lead to the increase of the survival rate of glia cells and their strengthened communication with neurons through axons during ischemia/reperfusion injury.

According to our research on ischemia/reperfusion animal model, *α*-BC probably acts as a neuroprotective molecule providing the early protection of neurons by giving intracellular supports through the maintenance of cytoskeleton and extracellular supports through the protection of glia cells, and its anti-inflammatory functions during stroke need to be further explored for the increased expression in multiple glia cells. Understanding of the exact interaction between *α*-BC and cytoskeleton in nerve cells and further calcification of *α*-BC-specific subgroup glia cells will not only provide new exciting insights into the mechanisms of the cerebral ischemia/reperfusion injury but also help us to find new treatment strategies for stroke and uncover the pathogenesis of many other neurological diseases.
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![Induction of MAP-2 (in green fluorescence) and *α*B-crystallin (*α*-BC) (in red fluorescence) in subcortical tissue sections and parietal cortex brain slices the in 7th day of reperfusion after transient global cerebral ischemia in Gerbil model of BCAO. *α*-BC-positive but MAP-2-negative nonneuronal glia cells (I, I′ and II, II′) (white arrow head) in subcortical tissue sections; co-expression of MAP-2 with *α*-BC in neurons of parietal cortex (III′′) (in yellow fluorescence); DAB (×40) and immunofluorescence staining (×40) of normal subcortical brain sections shows that the nucleus is surrounded by densely stained cytoplasm, and the staining is further extended into proximal segments of cytodendrites in *α*-BC-positive cells (IV, V and VI, VII). (Black arrow and white arrow head resp.).](OXIMED2012-945071.001){#fig1}

![Immunohistochemical findings (DAB × 20) of *α*-BC or MAP-2 in Gerbil brain sections of normal (A/E) and ischemia/reperfusion (I/R) 6 hours (B/F), 3 days (C/G), and 7 days (D/H) after occlusion. An increment in the number of *α*-BC-positive cells (black arrow head) was detected 6 hours after reperfusion and lasted until the 7th day after reperfusion; an immediate reduction of MAP-2-positive neurons in 6 hours after reperfusion was detected and began to recover after 3 days post-reperfusion, on the 7th day the number of MAP-2-positive neurons was almost normal.](OXIMED2012-945071.002){#fig2}

![Trendgram of *α*-BC (blue line) and MAP-2 (red line) in normal and ischemia/reperfusion Gerbil brains: an increment in the expression index of *α*-BC-positive cells and a sharp decrement and slow recovery expression index of MAP-2-positive cells in normal and BCAO in the 6 hours, 1 day, 3 days, and 7 days after reperfusion of Gerbil brains were detected and showed above.](OXIMED2012-945071.003){#fig3}
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